Patent Application for DNase Enzyme Therapy for Tumor Microenvironment Immunomodulation

This document is a published patent application from the USPTO detailing a novel therapeutic approach. The application, filed by CLS THERAPEUTICS LIMITED, describes methods for immunomodulating the immunosuppressive tumor microenvironment and preventing tumor microbiome effects through DNase enzyme therapy. The core of the invention involves administering deoxyribonuclease (DNase) enzyme, either as a standalone treatment or in combination with other immunomodulating agents.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in cancer therapeutics. Companies involved in drug development, particularly in oncology and immunotherapy, should monitor the progress of this patent application and related intellectual property in the therapeutic area of tumor microenvironment modulation.